Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study.
Aged
Anti-Bacterial Agents
/ therapeutic use
Antibiotic Prophylaxis
Bacteria
/ drug effects
Bacterial Infections
/ etiology
Catheters, Indwelling
/ adverse effects
Female
Humans
International Agencies
Male
Middle Aged
Peritoneal Dialysis
/ adverse effects
Peritonitis
/ etiology
Practice Patterns, Physicians'
/ standards
Prognosis
Prospective Studies
infection
peritoneal dialysis
peritonitis
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
11
10
2017
accepted:
29
05
2018
pubmed:
28
7
2018
medline:
1
5
2020
entrez:
28
7
2018
Statut:
ppublish
Résumé
Peritoneal dialysis (PD)-related infections lead to significant morbidity. The International Society for Peritoneal Dialysis (ISPD) guidelines for the prevention and treatment of PD-related infections are based on variable evidence. We describe practice patterns across facilities participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). PDOPPS, a prospective cohort study, enrolled nationally representative samples of PD patients in Australia/New Zealand (ANZ), Canada, Thailand, Japan, the UK and the USA. Data on PD-related infection prevention and treatment practices across facilities were obtained from a survey of medical directors'. A total of 170 centers, caring for >11 000 patients, were included. The proportion of facilities reporting antibiotic administration at the time of PD catheter insertion was lowest in the USA (63%) and highest in Canada and the UK (100%). Exit-site antimicrobial prophylaxis was variably used across countries, with Japan (4%) and Thailand (28%) having the lowest proportions. Exit-site mupirocin was the predominant exit-site prophylactic strategy in ANZ (56%), Canada (50%) and the UK (47%), while exit-site aminoglycosides were more common in the USA (72%). Empiric Gram-positive peritonitis treatment with vancomycin was most common in the UK (88%) and USA (83%) compared with 10-45% elsewhere. Empiric Gram-negative peritonitis treatment with aminoglycoside therapy was highest in ANZ (72%) and the UK (77%) compared with 10-45% elsewhere. Variation in PD-related infection prevention and treatment strategies exist across countries with limited uptake of ISPD guideline recommendations. Further work will aim to understand the impact these differences have on the wide variation in infection risk between facilities and other clinically relevant PD outcomes.
Sections du résumé
BACKGROUND
Peritoneal dialysis (PD)-related infections lead to significant morbidity. The International Society for Peritoneal Dialysis (ISPD) guidelines for the prevention and treatment of PD-related infections are based on variable evidence. We describe practice patterns across facilities participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).
METHODS
PDOPPS, a prospective cohort study, enrolled nationally representative samples of PD patients in Australia/New Zealand (ANZ), Canada, Thailand, Japan, the UK and the USA. Data on PD-related infection prevention and treatment practices across facilities were obtained from a survey of medical directors'.
RESULTS
A total of 170 centers, caring for >11 000 patients, were included. The proportion of facilities reporting antibiotic administration at the time of PD catheter insertion was lowest in the USA (63%) and highest in Canada and the UK (100%). Exit-site antimicrobial prophylaxis was variably used across countries, with Japan (4%) and Thailand (28%) having the lowest proportions. Exit-site mupirocin was the predominant exit-site prophylactic strategy in ANZ (56%), Canada (50%) and the UK (47%), while exit-site aminoglycosides were more common in the USA (72%). Empiric Gram-positive peritonitis treatment with vancomycin was most common in the UK (88%) and USA (83%) compared with 10-45% elsewhere. Empiric Gram-negative peritonitis treatment with aminoglycoside therapy was highest in ANZ (72%) and the UK (77%) compared with 10-45% elsewhere.
CONCLUSIONS
Variation in PD-related infection prevention and treatment strategies exist across countries with limited uptake of ISPD guideline recommendations. Further work will aim to understand the impact these differences have on the wide variation in infection risk between facilities and other clinically relevant PD outcomes.
Identifiants
pubmed: 30053214
pii: 5057652
doi: 10.1093/ndt/gfy204
pmc: PMC6887924
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2118-2126Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Références
Perit Dial Int. 2012 May-Jun;32(3):322-31
pubmed: 22135315
Perit Dial Int. 2011 Nov-Dec;31(6):651-62
pubmed: 21719685
Perit Dial Int. 2017 Mar-Apr;37(2):141-154
pubmed: 28360365
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1090-1099
pubmed: 28637862
Am J Kidney Dis. 1999 May;33(5):927-33
pubmed: 10213651
Kidney Int Rep. 2016 Jun 11;1(2):65-72
pubmed: 29142915
Am J Kidney Dis. 1996 Oct;28(4):549-52
pubmed: 8840945
Kidney Int. 2009 Sep;76(6):622-8
pubmed: 19516241
Scand J Urol Nephrol. 1992;26(2):177-80
pubmed: 1626207
PLoS One. 2013 Aug 01;8(8):e71532
pubmed: 23936514
Perit Dial Int. 2016 May-Jun;36(3):297-307
pubmed: 26526049
Perit Dial Int. 2016 9-10;36(5):481-508
pubmed: 27282851
J Am Soc Nephrol. 2005 Feb;16(2):539-45
pubmed: 15625071
Nephrol Dial Transplant. 2010 Feb;25(2):587-92
pubmed: 19679557
Am J Kidney Dis. 1993 Apr;21(4):446-8
pubmed: 8465827
J Am Soc Nephrol. 2012 Aug;23(8):1398-405
pubmed: 22626818
Nephrology (Carlton). 2011 Jan;16(1):19-29
pubmed: 21175973
Perit Dial Int. 2010 Nov-Dec;30(6):619-25
pubmed: 20634438
Perit Dial Int. 2007 Sep-Oct;27(5):560-4
pubmed: 17704448
Perit Dial Int. 2008 Sep-Oct;28(5):505-8
pubmed: 18708544
Kidney Int Suppl. 2003 Dec;(88):S3-12
pubmed: 14870873
J Am Soc Nephrol. 1996 Oct;7(10):2176-82
pubmed: 8915978
Perit Dial Int. 2014 Nov-Dec;34(7):791-5
pubmed: 25520483
Ren Fail. 2008;30(4):417-22
pubmed: 18569916
Nephrology (Carlton). 2016 Jul;21(7):535-46
pubmed: 26807739
Am J Kidney Dis. 2002 Feb;39(2):337-41
pubmed: 11840374
Perit Dial Int. 2016 9-10;36(5):509-18
pubmed: 26764341
Perit Dial Int. 2012 Sep-Oct;32(5):525-30
pubmed: 22302770
Kidney Int Suppl. 2006 Nov;(103):S55-62
pubmed: 17080112
Am J Kidney Dis. 2002 Jul;40(1):152-60
pubmed: 12087573
Am J Kidney Dis. 2000 Nov;36(5):1014-9
pubmed: 11054359
Am J Kidney Dis. 2014 Aug;64(2):278-89
pubmed: 24751170
Adv Perit Dial. 2009;25:56-9
pubmed: 19886318
Cochrane Database Syst Rev. 2017 Apr 08;4:CD004679
pubmed: 28390069
Gut Liver. 2014 Jan;8(1):1-6
pubmed: 24516694
Nephrol Dial Transplant. 1997 Jan;12(1):157-60
pubmed: 9027792
Cochrane Database Syst Rev. 2014 Apr 26;(4):CD005284
pubmed: 24771351